Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
77.62
-0.56 (-0.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
47
48
Next >
Stocks That Hit 52-Week Highs On Thursday
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
AstraZeneca Bets $25M On Preclinical Bispecific Antibody
April 07, 2022
Via
Benzinga
Danaher Joins Elite List Of Stocks With 95-Plus Composite Rating
April 06, 2022
On Wednesday, Danaher got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
Via
Investor's Business Daily
AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study
March 24, 2022
Via
Benzinga
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?
April 07, 2022
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier.
Via
Benzinga
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
April 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ
April 07, 2022
According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for...
Via
Benzinga
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
April 06, 2022
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market...
Via
Benzinga
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
April 06, 2022
Via
Benzinga
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
April 04, 2022
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have
Via
Benzinga
Top Nasdaq 100 Stocks: Trading Opportunities For Next Week
April 03, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some Nasdaq 100 stock opportunities by...
Via
Talk Markets
Mitt Romney Says Senators Reached Tentative $10B Deal In Additional COVID-19 Relief Funding: CNBC
April 01, 2022
Via
Benzinga
Omicron More Severe For Unvaccinated Children Than Other Strains, Hong Kong Study Finds: Bloomberg
March 31, 2022
According to a Hong Kong-based study, the omicron variant of COVID-19 has been linked to more hospitalizations, severe complicat
Via
Benzinga
3 Vaccine Stocks to Buy on the New Covid Variant Surge
March 31, 2022
These vaccine stocks are likely to trend higher with the recent surge in covid-19 cases and concerns related to a new variant.
Via
InvestorPlace
Omicron BA.2 Variant Represents More Than 50% COVID-19 Cases, Says CDC Estimates: WSJ
March 30, 2022
According to the Centers for Disease Control and Prevention estimates, the omicron BA.2 variant represents approximately 55% of new COVID-19 cases in the U.S., as signs suggest infections are edging...
Via
Benzinga
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
March 29, 2022
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country
Via
Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers
March 29, 2022
Pre-open movers
Via
Benzinga
Biotech Funds and ETFs Continue to Lag
March 28, 2022
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...
Via
Talk Markets
EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld
March 24, 2022
EMA's human medicines committee (CHMP) has
Via
Benzinga
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
March 24, 2022
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.
Via
Investor's Business Daily
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
March 24, 2022
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection.
Via
Benzinga
AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters
March 23, 2022
European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ: AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections,
Via
Benzinga
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
March 23, 2022
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 1.6% on an annualized basis producing an average annual return of 15.33%. Currently, AstraZeneca has...
Via
Benzinga
Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents
March 21, 2022
Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.
Via
Benzinga
Morning Brief: Top Stories Dominating Financial Media on Monday, March 21
March 21, 2022
CNBC Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant,...
Via
Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
March 21, 2022
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases.
Via
Benzinga
AstraZeneca's COVID-19 Antibody Neutralizes Omicron Sub-variants, Lab Study Shows
March 21, 2022
AstraZeneca Plc's (NASDAQ: AZN) antibody-based cocktail to prevent and treat COVID-19 retained
Via
Benzinga
AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT
March 18, 2022
Citing AstraZeneca Plc's (NASDAQ: AZN) head of research and development, the Financial Times reported that the Company
Via
Benzinga
Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron
March 17, 2022
Via
Benzinga
AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai
March 17, 2022
Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.